KIDS vs NVAX: fair value comparison
OrthoPediatrics Corp. and Novavax, Inc. · Updated 2026-10-19
KIDS has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. NVAX has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, KIDS currently ranks higher by quality score.
| KIDS | NVAX | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $21.95 | $11.26 |
| 12-month range | $14.64–$26.50 | $6.22–$12.82 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #84 of 301 Healthcare | #86 of 301 Healthcare |
| Quality grade | C | C |
| Leverage | Low | Low |
| Margin trend | Expanding | Expanding |
| Revenue growth | High | High |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Uptrend |
| 52-week position | The upper-middle quarter | The top quarter |
Full single-stock breakdowns: KIDS fair value analysis · NVAX fair value analysis